{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:50:54Z","timestamp":1721065854268},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whereas Huntington\u2019s disease (HD) is unequivocally a neurological disorder, a critical mass of emerging studies highlights the occurrence of peripheral pathology like cardiovascular defects in both animal models and humans. The overt impairment in cardiac function is normally expected to be associated with peripheral vascular dysfunction, however whether this assumption is reasonable or not in HD is still unknown. In this study we functionally characterized the vascular system in R6\/2 mouse model (line 160 CAG), which recapitulates several features of human pathology including cardiac disease. Vascular reactivity in different arterial districts was determined by wire myography in symptomatic R6\/2 mice and age-matched wild type (WT) littermates. Disease stage was assessed by using well-validated behavioural tests like rotarod and horizontal ladder task. Surprisingly, no signs of vascular dysfunction were detectable in symptomatic mice and no link with motor phenotype was found.<\/jats:p>","DOI":"10.1038\/srep42797","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T10:15:53Z","timestamp":1487326553000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington\u2019s disease transgenic R6\/2 (160 CAG) mice"],"prefix":"10.1038","volume":"7","author":[{"given":"A.","family":"Di Pardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Carrizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Damato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Capocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pompeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. C.","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Puca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Remondelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Maglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Vecchione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"BFsrep42797_CR1","unstructured":"Bates, G., Harper, P. S. & Jones, L. Huntington\u2019s Disease. Oxford University Press 3rd edn, 3\u201327 (2002)."},{"key":"BFsrep42797_CR2","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","volume":"330","author":"B Kremer","year":"1994","unstructured":"Kremer, B. et al. A worldwide study of the Huntington\u2019s disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 330, 1401\u20131406 (1994).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep42797_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1086\/318193","volume":"68","author":"D Falush","year":"2000","unstructured":"Falush, D., Almqvist, E. W., Brinkmann, R. R., Iwasa, Y. & Hayden, M. R. Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. Am. J. Hum. Genet. 68, 373\u2013385 (2000).","journal-title":"Am. J. Hum. Genet."},{"key":"BFsrep42797_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker, F. O. Huntington\u2019s disease. Lancet 369, 218\u2013228 (2007).","journal-title":"Lancet"},{"key":"BFsrep42797_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5694\/j.1326-5377.1982.tb132224.x","volume":"1","author":"E Chiu","year":"1982","unstructured":"Chiu, E. & Alexander, L. Causes of death in Huntington\u2019s disease. Med J Aust. 1, 153 (1982).","journal-title":"Med J Aust."},{"key":"BFsrep42797_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1212\/WNL.38.5.769","volume":"38","author":"DJ Lanska","year":"1988","unstructured":"Lanska, D. J., Lavine, L., Lanska, M. J. & Schoenberg, B. S. Huntington\u2019s disease mortality in the United States. Neurology 38, 769\u2013772 (1988).","journal-title":"Neurology"},{"key":"BFsrep42797_CR7","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/j.1468-1331.2010.02973.x","volume":"8","author":"NA Aziz","year":"2010","unstructured":"Aziz, N. A., Anguelova, G. V., Marinus, J., van Dijk, J. G. & Roos, R. A. Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington\u2019s disease. Eur J Neurol. 8, 1068\u201374 (2010).","journal-title":"Eur J Neurol."},{"key":"BFsrep42797_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1600-0404.2009.01251.x","volume":"121","author":"J Kobal","year":"2010","unstructured":"Kobal, J. et al. Autonomic dysfunction in presymptomatic and early symptomatic Huntington\u2019s disease. Acta Neurol Scand. 121, 392\u2013399 (2010).","journal-title":"Acta Neurol Scand."},{"key":"BFsrep42797_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1136\/jnnp.72.6.726","volume":"72","author":"J Andrich","year":"2002","unstructured":"Andrich, J. et al. Autonomic nervous system function in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 72, 726\u201331 (2002).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFsrep42797_CR10","doi-asserted-by":"publisher","first-page":"e0147269","DOI":"10.1371\/journal.pone.0147269","volume":"11","author":"AM Schroeder","year":"2016","unstructured":"Schroeder, A. M. et al. Cardiac Dysfunction in the BACHD Mouse Model of Huntington\u2019s Disease. PLoS One 11, e0147269 (2016).","journal-title":"PLoS One"},{"key":"BFsrep42797_CR11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/JHD-2012-120004","volume":"1","author":"NI Wood","year":"2012","unstructured":"Wood, N. I. et al. Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington\u2019s disease. J Huntingtons Dis. 1, 57\u201364 (2012).","journal-title":"J Huntingtons Dis."},{"key":"BFsrep42797_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.nbd.2006.09.016","volume":"25","author":"MJ Mihm","year":"2007","unstructured":"Mihm, M. J. et al. Cardiac dysfunction in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol Dis 25, 297\u2013308 (2007).","journal-title":"Neurobiol Dis"},{"key":"BFsrep42797_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ana.24406","volume":"78","author":"J Drouin-Ouellet","year":"2015","unstructured":"Drouin-Ouellet, J. et al. Cerebrovascular and blood-brain barrier impairments in Huntington\u2019s disease: Potential implications for its pathophysiology. Ann Neurol. 78, 160\u201377 (2015).","journal-title":"Ann Neurol."},{"key":"BFsrep42797_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ejphar.2012.10.026","volume":"698","author":"A Rahman","year":"2013","unstructured":"Rahman, A. et al. Late onset vascular dysfunction in the R6\/1 model of Huntington\u2019s disease. Eur J Pharmacol. 698, 345\u201353 (2013).","journal-title":"Eur J Pharmacol."},{"key":"BFsrep42797_CR15","doi-asserted-by":"publisher","first-page":"25979","DOI":"10.1038\/srep25979","volume":"6","author":"AD Kane","year":"2016","unstructured":"Kane, A. D., Niu, Y., Herrera, E. A., Morton, A. J. & Giussani, D. A. Impaired Nitric Oxide Mediated Vasodilation In The Peripheral Circulation In The R6\/2 Mouse Model Of Huntington\u2019s Disease. Sci Rep. 6, 25979 (2016).","journal-title":"Sci Rep."},{"key":"BFsrep42797_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87, 493\u2013506 (1996).","journal-title":"Cell"},{"key":"BFsrep42797_CR17","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","volume":"19","author":"RJ Carter","year":"1999","unstructured":"Carter, R. J. et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington\u2019s disease mutation. J Neurosci. 19, 3248\u201357 (1999).","journal-title":"J Neurosci."},{"key":"BFsrep42797_CR18","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1073\/pnas.1114502109","volume":"109","author":"A Di Pardo","year":"2012","unstructured":"Di Pardo, A. et al. Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci USA 109, 3528\u201333 (2012).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep42797_CR19","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/mnfr.201600233","volume":"60","author":"A Carrizzo","year":"2016","unstructured":"Carrizzo, A. et al. Morus alba extract modulates blood pressure homeostasis through eNOS signaling. Mol Nutr Food Res. 60, 2304\u20132311 (2016).","journal-title":"Mol Nutr Food Res."},{"key":"BFsrep42797_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","volume":"2","author":"JY Li","year":"2005","unstructured":"Li, J. Y., Popovic, N. & Brundin, P. The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies. NeuroRx. 2, 447\u201364 (2005).","journal-title":"NeuroRx."},{"key":"BFsrep42797_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00394-012-0320-x","volume":"52","author":"A Aggio","year":"2013","unstructured":"Aggio, A. et al. Endothelium\/nitric oxide mechanism mediates vasorelaxation and counteracts vasoconstriction induced by low concentration of flavanols. Eur J Nutr. 52, 263\u201372 (2013).","journal-title":"Eur J Nutr."},{"key":"BFsrep42797_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1161\/01.HYP.36.1.97","volume":"36","author":"T Yamashita","year":"2000","unstructured":"Yamashita, T. et al. Mechanisms of Reduced Nitric Oxide\/cGMP\u2013Mediated Vasorelaxation in Transgenic Mice Overexpressing Endothelial Nitric Oxide Synthase. Hypertension 36, 97\u2013102 (2000).","journal-title":"Hypertension"},{"key":"BFsrep42797_CR23","doi-asserted-by":"publisher","first-page":"e89745","DOI":"10.1371\/journal.pone.0089745","volume":"9","author":"A Carrizzo","year":"2014","unstructured":"Carrizzo, A. et al. Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease. PLoS One 9, e89745 (2014).","journal-title":"PLoS One"},{"key":"BFsrep42797_CR24","doi-asserted-by":"publisher","first-page":"e1058464","DOI":"10.1080\/21675511.2015.1058464","volume":"3","author":"M Mielcarek","year":"2015","unstructured":"Mielcarek, M. Huntington\u2019s disease is a multi-system disorder. Rare Dis. 3, e1058464 (2015).","journal-title":"Rare Dis"},{"key":"BFsrep42797_CR25","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.113.302549","volume":"114","author":"MJ Shen","year":"2014","unstructured":"Shen, M. J. & Zipes, D. P. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 114, 1004\u20131021 (2014).","journal-title":"Circ Res."},{"key":"BFsrep42797_CR26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/JHD-130054","volume":"2","author":"M Abildtrup","year":"2013","unstructured":"Abildtrup, M. & Shattock, M. Cardiac Dysautonomia in Huntington\u2019s Disease. J Huntingtons Dis. 2, 251\u201361 (2013).","journal-title":"J Huntingtons Dis."},{"key":"BFsrep42797_CR27","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1113\/jphysiol.2012.238113","volume":"590","author":"H Kiriazis","year":"2012","unstructured":"Kiriazis, H. et al. Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington\u2019s disease. J Physiol. 590, 5845\u201360 (2012).","journal-title":"J Physiol."},{"key":"BFsrep42797_CR28","doi-asserted-by":"publisher","first-page":"e1004550","DOI":"10.1371\/journal.pgen.1004550","volume":"10","author":"M Mielcarek","year":"2014","unstructured":"Mielcarek, M. et al. Dysfunction of the CNS-heart axis in mouse models of Huntington\u2019s disease. PLoS Genet. 10, e1004550 (2014).","journal-title":"PLoS Genet."},{"key":"BFsrep42797_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1152\/jn.00762.2011","volume":"107","author":"DM Cummings","year":"2012","unstructured":"Cummings, D. M. et al. A critical window of CAG repeat-length correlates with phenotype severity in the R6\/2 mouse model of Huntington\u2019s disease. J Neurophysiol. 107, 677\u201391 (2012).","journal-title":"J Neurophysiol."},{"key":"BFsrep42797_CR30","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","volume":"23","author":"A Di Pardo","year":"2014","unstructured":"Di Pardo, A. et al. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet. 23, 2251\u201365 (2014).","journal-title":"Hum Mol Genet"},{"key":"BFsrep42797_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nbd.2011.02.008","volume":"42","author":"B Tang","year":"2011","unstructured":"Tang, B. et al. Gene expression profiling of R6\/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington\u2019s disease. Neurobiol Dis. 42, 459\u201367 (2011).","journal-title":"Neurobiol Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep42797","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42797.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42797.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T19:59:09Z","timestamp":1671825549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep42797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,27]]}},"alternative-id":["BFsrep42797"],"URL":"https:\/\/doi.org\/10.1038\/srep42797","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]},"assertion":[{"value":"22 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42797"}}